Schrodinger sees FY23 software revenue growth 13%-17%

Drug discovery revenue is expected to range from $70 million to $90 million; Software gross margin is expected to be similar to software gross margin for the full year 2022; Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022 and to be similar to revenue growth in 2023; Cash used for operating activities in 2023 is expected to be below cash used for operating activities in 2022